About sn-1-specific diacylglycerol lipase ABHD11
sn-1-specific diacylglycerol lipase ABHD11 (ABHD11) is a protein
from Homo sapiens identified by UniProt accession
Q8NFV4, 306 residues long.
MolForge cross-references it against 0 known binders and
115 disease associations.
Target properties
| Protein name | sn-1-specific diacylglycerol lipase ABHD11 |
|---|
| UniProt accession | Q8NFV4 |
|---|
| Gene | ABHD11 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 306 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (115)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- mean platelet volume · score 0.33
- platelet component distribution width · score 0.29
- papillary thyroid carcinoma · score 0.10
- urinary bladder carcinoma · score 0.07
- retinitis pigmentosa · score 0.06
- triple-negative breast cancer · score 0.05
- Familial exudative vitreoretinopathy · score 0.05
- balding measurement · score 0.05
- breast cancer · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8NFV4-F1 | alphafold | PREDICTED | 88.05 | — |
Amino-acid sequence (306 residues)
MLRWTRAWRL PREGLGPHGP SFARVPVAPS SSSGGRGGAE PRPLPLSYRL LDGEAALPAV VFLHGLFGSK TNFNSIAKIL AQQTGRRVLT VDARNHGDSP HSPDMSYEIM SQDLQDLLPQ LGLVPCVVVG HSMGGKTAML LALQRPELVE RLIAVDISPV ESTGVSHFAT YVAAMRAINI ADELPRSRAR KLADEQLSSV IQDMAVRQHL LTNLVEVDGR FVWRVNLDAL TQHLDKILAF PQRQESYLGP TLFLLGGNSQ FVHPSHHPEI MRLFPRAQMQ TVPNAGHWIH ADRPQDFIAA IRGFLV
Explore sn-1-specific diacylglycerol lipase ABHD11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets